Latest Financial Results
Stock Information
Company Overview
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.
Contact Information
Investor Relations
JTC Team, LLC.
Jenene Thomas
T: 833-475-8247
xbio@jtcir.com
Transfer Agent
Empire Stock Transfer, Inc.
1859 Whitney Mesa Drive
Henderson, NV 89014
T: 702-818-5898